Nanomaterials for Cancer Diagnostics and Therapeutics
Under the co-leadership of Drs. Chad Mirkin, driving the nanotechnology effort, and Steven Rosen, driving the clinical translational oncology effort, the NU-CCNE represents a strongly integrated partnership between the International Institute for Nanotechnology and the Robert H. Lurie Comprehensive Cancer Center. The primary goal of this new NU-CCNE program is to advance nanotechnology discoveries (e.g., materials, tools, and devices) for brain, breast, and pancreatic cancer diagnostics, imaging, and therapeutics that have strong potential for clinical utility and for use in many other forms of cancer research and treatment.
Chad A. Mirkin, Ph.D.
Steven T. Rosen, M.D.
- Project 1: NanoFlares for the Detection of Cancer Stem Cells
- Project 2: Theranostic Magnetic Nanostructures for the Molecular Imaging of Cancer
- Project 3: Nanostructured Matrices for Cancer Cell Biology
- Project 4: Preclinical Validation of Polyvalent siRNA Gold Nanoparticle Conjugates as Anti-glioma Therapeutics